— Know what they know.
Not Investment Advice

IART NASDAQ

Integra LifeSciences Holdings Corporation
1W: -10.1% 1M: -26.3% 3M: -27.3% YTD: -0.2% 1Y: -25.6% 3Y: -68.4% 5Y: -82.5%
$11.99
-0.11 (-0.91%)
 
Weekly Expected Move ±13.3%
$9 $10 $12 $13 $15
NASDAQ · Healthcare · Medical - Devices · Tech Score Strong Sell · Power 32 · $932.5M mcap · 59M float · 1.65% daily turnover · Short 60% of daily vol
Credit Risk of going bust: higher than 87% of companies Debt: 68.2% of company value Bonds: none of note held by US funds details ▾
Of US companies ranked in the second-riskiest tenth, about 1 in 87 filed for bankruptcy within a year (2020-2025).
If the stock fell to about $1.86 (down 84%), Integra LifeSciences Holdings Corporation would be worth roughly what it owes.
Total debt $2.00B against a stock market value of $932.5M.
Distance to default 1.92 (Merton model): prices to 2026-10-27, balance sheet 2026-09-30, debt counted $937.5M (short-term plus half of long-term), stock volatility 65.9%; Altman Z 1.28. A ranking and a back-test, not a forecast.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
Smart Money Score
Watch 25
Insider—
Congress—
ETF Holdings—
Key Statistics
Market Cap$932.5M
52W Range8.7-20.49
Volume1,431,835
Avg Volume969,297
Beta1.21
Dividend—
Analyst Ratings
12 Buy 12 Hold 4 Sell
Consensus Buy
Company Info
CEOStuart Essig
Employees4,427
SectorHealthcare
IndustryMedical - Devices
IPO Date1995-08-16
1100 Campus Road
Princeton, NJ 08540
US
609 275 0500
About Integra LifeSciences Holdings Corporation

Integra LifeSciences Holdings Corporation is a medical technology company focused on the creation, production, and global distribution of advanced surgical implants and instruments. These products are utilized across various medical fields, including neurosurgery, limb reconstruction, and general surgical procedures. The company operates through two primary business segments: Codman Specialty Surgical and Tissue Technologies. The Codman Specialty Surgical division offers a comprehensive range of neurosurgical and neuro-critical care products. This includes specialized equipment for tissue ablation, dural repair solutions, cerebral spinal fluid management systems, intracranial monitoring tools, and cranial stabilization devices. Additionally, this segment provides surgical headlamps, various instrumentation, and supports these offerings with asset management software, technical assistance, and after-market services. Integra also supplies an extensive catalog of approximately 40,000 surgical instrument designs, along with a wide selection of surgical and lighting products. Its clientele spans hospitals, surgical centers, and extends to dental, podiatry, and veterinary practices. The Tissue Technologies segment specializes in innovative regenerative technology products for the treatment of both acute and chronic wounds. It further provides surgical tissue repair solutions for a multitude of applications, such as hernia repair, peripheral nerve protection and regeneration, and tendon reconstruction. This encompasses a broad array of offerings for skin and wound repair, plastic and reconstructive surgery products, bone grafting materials, and specialized nerve and tendon repair products. Integra LifeSciences distributes its diverse product portfolio internationally, reaching markets throughout the United States, Europe, Asia Pacific, and other global regions. Distribution is managed directly through its dedicated sales forces and various other channels, serving a wide array of healthcare entities including hospitals, integrated health networks, group purchasing organizations, individual clinicians, surgery centers, and other healthcare providers. Founded in 1989, Integra LifeSciences Holdings Corporation is headquartered in Princeton, New Jersey.

Recent Insider Trades

NameTypeSharesPriceDate
Caruso Andrea B 0 — 2026-10-01
Caruso Andrea B 4,375 $43.39 2026-10-01
Caruso Andrea B 2,634 $68.10 2026-10-01
Caruso Andrea B 2,674 $65.11 2026-10-01
Caruso Andrea B 3,244 $52.87 2026-10-01

Sign in to InsiderStreet

You'll also get our free weekly newsletter with
smart money signals, market insights, and alpha ideas.
Unsubscribe anytime.

For informational purposes only. Not investment advice. Data sourced from SEC filings. Privacy Terms